Trading Report: Today, 113 Shares of Medtronic PLC (MDT) are sold by First Financial Bank N.A. Trust Division

Today, 113 Shares of Medtronic PLC (MDT) are sold by First Financial Bank N.A. Trust Division

First Financial Bank N.A. Trust Division decreased its position in shares of Medtronic PLC (NYSE:MDT) by 0.7% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 16,143 shares of the medical technology company’s stock after selling 113 shares during the period. First Financial Bank N.A. Trust Division’s holdings in Medtronic PLC were worth $1,395,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in MDT. Nepsis Capital Management Inc. boosted its stake in shares of Medtronic PLC by 3.7% in the third quarter. Nepsis Capital Management Inc. now owns 62,137 shares of the medical technology company’s stock valued at $5,369,000 after buying an additional 2,231 shares during the last quarter. Fisher Asset Management LLC boosted its stake in shares of Medtronic PLC by 4.9% in the third quarter. Fisher Asset Management LLC now owns 4,949 shares of the medical technology company’s stock valued at $428,000 after buying an additional 233 shares during the last quarter. Oregon Public Employees Retirement Fund boosted its stake in shares of Medtronic PLC by 43.1% in the third quarter. Oregon Public Employees Retirement Fund now owns 300,418 shares of the medical technology company’s stock valued at $25,956,000 after buying an additional 90,433 shares during the last quarter. Kelman Lazarov Inc. boosted its stake in shares of Medtronic PLC by 8.2% in the third quarter. Kelman Lazarov Inc. now owns 1,642 shares of the medical technology company’s stock valued at $141,000 after buying an additional 125 shares during the last quarter. Finally, Stillwater Capital Advisors LLC boosted its stake in shares of Medtronic PLC by 1.1% in the third quarter. Stillwater Capital Advisors LLC now owns 114,096 shares of the medical technology company’s stock valued at $9,858,000 after buying an additional 1,257 shares during the last quarter. Institutional investors own 80.95% of the company’s stock.

Medtronic PLC (NYSE:MDT) traded down 2.03% during midday trading on Monday, reaching $73.99. 7,525,125 shares of the company were exchanged. Medtronic PLC has a 52 week low of $71.03 and a 52 week high of $89.27. The firm has a 50-day moving average price of $81.50 and a 200-day moving average price of $84.68. The company has a market capitalization of $102.25 billion, a PE ratio of 28.79 and a beta of 1.01.

Medtronic PLC (NYSE:MDT) last announced its quarterly earnings results on Tuesday, November 22nd. The medical technology company reported $1.12 earnings per share for the quarter, beating analysts’ consensus estimates of $1.11 by $0.01. Medtronic PLC had a net margin of 14.63% and a return on equity of 12.36%. The business earned $7.35 billion during the quarter, compared to analysts’ expectations of $7.46 billion. During the same period last year, the business earned $1.03 earnings per share. The business’s revenue for the quarter was up 4.1% on a year-over-year basis. Equities research analysts anticipate that Medtronic PLC will post $4.63 earnings per share for the current fiscal year.

Several analysts have commented on the stock. Deutsche Bank AG reiterated a “buy” rating on shares of Medtronic PLC in a research note on Monday, October 31st. Jefferies Group reduced their target price on shares of Medtronic PLC from $100.00 to $88.00 and set a “buy” rating on the stock in a report on Wednesday, November 23rd. Oppenheimer Holdings Inc. reduced their target price on shares of Medtronic PLC from $94.00 to $84.00 and set an “outperform” rating on the stock in a report on Wednesday, November 23rd. BMO Capital Markets reduced their target price on shares of Medtronic PLC from $94.00 to $87.00 and set an “outperform” rating on the stock in a report on Wednesday, November 23rd. Finally, Barclays PLC reduced their target price on shares of Medtronic PLC from $93.00 to $85.00 and set an “overweight” rating on the stock in a report on Wednesday, November 23rd. Seven analysts have rated the stock with a hold rating and twenty have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $88.19.

In related news, Director James T. Lenehan purchased 2,000 shares of the company’s stock in a transaction on Wednesday, November 23rd. The stock was acquired at an average cost of $73.27 per share, for a total transaction of $146,540.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Omar Ishrak sold 61,925 shares of Medtronic PLC stock in a transaction dated Thursday, September 15th. The shares were sold at an average price of $84.93, for a total transaction of $5,259,290.25. Following the sale, the chief executive officer now owns 565,916 shares of the company’s stock, valued at $48,063,245.88. The disclosure for this sale can be found here. Company insiders own 0.25% of the company’s stock.

About Medtronic PLC

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

Related posts

Leave a Comment